Conclusions. A limited number of genetic lineages caused the majority of invasive meningococcal infections. A substantial proportion of isolates had evidence of capsular switching. The high prevalence of capsular switching requires surveillance to detect changes in the meningococcal population structure that may affect the effectiveness of meningococcal vaccines.
of serogroup B strains causing endemic disease, this serogroup will most likely not be covered by available vaccines for at least the next several years.
N. meningitidis has a highly plastic genome and multiple genetic mechanisms to alter its antigenic profile. One of the mechanisms is allelic replacement by transformation and homologous recombination of genes involved in capsule biosynthesis [9] . These are not just theoretical concerns, as both capsular switching or noncapsular antigenic shifts have been observed in the United States and worldwide [9] [10] [11] [12] [13] [14] . As examples, serogroup C strains with genotypes identical to those of serogroup B clonal strains causing outbreaks have been found [9] . Also, a serogroup W-135 clone emerged in 2000 to cause outbreaks of meningococcal disease among Hajj pilgrims and subsequently caused large epidemics in parts of sub-Saharan Africa and case clusters in other parts of the world [11] . Genetically, the epidemic clone belonged to the sequence type (ST)-11 clonal complex, which is typically associated with invasive serogroup C meningococcal strains, suggesting that capsular switching had occurred. These data suggest that serogroups not covered by MCV4 could emerge by a similar mechanism. In fact, capsular switching has been observed since licensure of the pediatric heptavalent pneumococcal polysaccharide protein conjugate vaccine (PCV7). Although PCV7 has been a huge public health success, there has been a marked increase in some nonvaccine pneumococcal serotypes, including apparent capsular switching from vaccine serotypes [15] [16] [17] [18] [19] . This has prompted the development of new pneumococcal conjugate vaccines that include additional serotypes. Similarly, capsular switching of virulent lineages of N. meningitidis of serogroups A, C, Y, and W-135 that are currently covered by MCV4 could lead to the selection of additional virulent serogroup B strains.
Multilocus sequence typing (MLST) of N. meningitidis, based on DNA sequencing of segments of 7 housekeeping genes, is a standard molecular subtyping approach for determining the genetic lineage of this organism. MLST is also used to infer capsular switching, which is presumed to have occurred when 2 meningococcal isolates share the same ST or clonal complex but differ in their polysaccharide capsule. DNA sequencing of genes that encode outer membrane proteins (OMPs) further discriminates among STs and provides additional molecular epidemiologic characterization of meningococcal strains [10, 20] . Together, MLST and OMP genotype profile data provide useful epidemiologic information regarding changes in meningococcal population structure over time.
Information about the population structure of N. meningitidis and the prevalence of capsular switching events is insufficient. The purpose of the present study was to determine, during the 6-year period before MCV4 licensure, the population structure of invasive N. meningitidis in the United States and to identify the proportion of meningococcal isolates that demonstrated capsular switching.
METHODS
Study isolates and determination of serogroup. Study isolates were obtained through active, laboratory-based surveillance from 1 January 2000 through 31 December 2005, from 10 Active Bacterial Core surveillance (ABCs) sites. ABCs is a component of the Centers for Disease Control and Prevention (CDC) Emerging Infections Program Network [21] . Because MCV4 was licensed in May 2005 and initial vaccine uptake was slow, the entire study period was considered to be the pre-MCV4 era [22] .
The following ABCs sites participated: California (3 counties in the San Francisco Bay area), Colorado (5 counties), Connecticut, Georgia, Maryland, Minnesota, New Mexico, New York (15 counties in the Rochester and Albany areas), Oregon, and Tennessee (11 counties). Not all areas participated throughout the study period. According to postcensus estimates, the population under surveillance during 2005 was ∼39.5 million persons, which is ∼13% of the US population.
The case definition for invasive meningococcal disease is the isolation of N. meningitidis from a normally sterile body fluid from an ABCs site resident [23, 24] . Laboratory audits are conducted to identify previously unreported cases.
Laboratory assays. Laboratory work for this study was performed at the CDC and the University of Pittsburgh. Serogrouping was performed as described elsewhere [25] . Isolates with discrepant phenotypic serogroup results between the submitting laboratories and CDC or that were not groupable underwent serogroup-specific polymerase chain reaction (SGS-PCR) [26] . For isolates with discrepancies between serogrouping and SGS-PCR, the SGS-PCR results were used.
MLST was performed to determine the genetic lineage of each meningococcal isolate and to identify capsular switching [27] . To further define specific meningococcal clones that had undergone capsular switching, OMP gene sequencing of porA variable region (VR) 1 and 2, porB, and fetA VR was performed as described elsewhere [28] [29] [30] [31] [32] . DNA sequences were determined using forward and reverse strands.
For clones that had undergone capsular switching (defined below), MLST and SGS-PCR were repeated, using the same template DNA for both tests in the same laboratory at the University of Pittsburgh. For these isolates, the final serogroup result was taken to be the result of the SGS-PCR.
Data analysis. Assembly of MLST sequences was performed using the Staden sequence analysis package (version 1.5.3) or Lasergene software (version 8; DNAStar). Sequence Typing Analysis and Retrieval System software (version 1.2a) was used for the determination of alleles [33] . The assignment of sequence types (STs), clonal complexes, and porA, porB, and [34, 35] .
Capsular switching in a meningococcal isolate was defined as an ST in an isolate of a serogroup not generally associated with that clonal complex and commonly associated with another serogroup. Bionumerics software (version 5.10; Applied Maths) was used to create minimum spanning trees [36] . The ST with the greatest number of single-locus variants was defined as the founder ST.
RESULTS
During the study period, 1301 meningococcal cases met the ABCs case definition. The study was conducted during a time of declining and unusually low meningococcal disease incidence in the United States [1, 37, 38] .
Of the 1301 ABCs cases occurring during the study period, isolates were available for 1160 (89.2%) ( (Table 2 and Figure 2) . The serogroup C early and late clones that were identified in Maryland in the 1990s were the predominant clones, differing only at the fetA locus (2-2:P1.5,2:F1-30 [25 {11 .7%}] and 2-2: P1.5,2:F3-6 [46 {21 .5%}], respectively) [10] . There were 20 ST-103 clonal complex isolates [44] . Most of these isolates ( which belonged to ST-4789, part of the ST-5 clonal complex (Table 2 ). There were 2 serogroup X isolates. One was ST-2980, which belongs to the ST-175 clonal complex and is usually associated with serogroup W-135, and the other was an ST-103 complex isolate, which is usually associated with serogroup C. Deletion of OMP genes. There were 7 isolates with evidence of porA deletion-2 serogroup C, 3 serogroup B, 1 serogroup W-135, and 1 serogroup Y isolates (Table 2 ) [10] . In addition, there were 4 serogroup B and 2 serogroup C isolates with evidence of fetA deletion [45, 46] . One nongroupable ST-41/ 44 isolate had a single-nucleotide substitution in the fetA coding region, which resulted in a frameshift mutation and a protein that is predicted to be nonfunctional. Capsular switching. Capsular switching was observed in 8 (1.5%) of the serogroup B isolates, 36 (12.9%) of the serogroup C isolates, none of the serogroup W-135 isolates, both (100%) of the serogroup X isolates, and 3 (0.9%) of the serogroup Y isolates (Figures 1-4) . The frequency of capsular switching observed among serogroup C isolates was statistically significantly higher than that observed among serogroup B or Y isolates ( ) . P ! .001
Of To determine whether capsular switching could be identified within specific meningococcal clones, as defined by MLST and OMP genotype profile, we further analyzed by OMP genotyping isolates that had demonstrated switching. Eight meningococcal clones that had undergone capsular switching were identified (Table 3) . For example, a serogroup C to serogroup B switch occurred within an ST-11 2-2:P1.22,14:F1-30 clone. Similarly, a serogroup B to serogroup C switch was identified within an ST-32 3-24:P1.7,16:F3-3 clone. In many instances, there was overlap by ABCs site and year in the presence of isolates of both serogroups, representing capsular switching within a specific clone (Table 3) .
DISCUSSION
This study defines the population structure and OMP genotype profile of invasive N. meningitidis isolates circulating in the United States during the 6 years before licensure of MCV4, as well as isolates that had undergone capsular switching. To our knowledge, this is the first population-based assessment of capsular switching prevalence among invasive meningococcal isolates.
As expected, the population of invasive isolates was primarily composed of a select group of recognized hypervirulent lineages. ST-11, ST-23, and ST-22 clonal complexes accounted for the majority of isolates belonging to serogroup C, Y, and W-135, respectively. For serogroup B, clonal complexes ST-32 and ST-41/44 predominated. In addition to their presence in the United States, these lineages have a global distribution [1] .
A substantial proportion of invasive serogroup C, Y, and B isolates demonstrated capsular switching, indicating that this is a common natural phenomenon in N. meningitidis. These isolates retain their invasiveness; however, during the period of this study the isolates that arose through capsular switching caused less disease than the isolates from the same genetic lineage of the original serogroup. For example, there was only 1 serogroup B, ST-11 isolate, whereas ST-11 isolates made up the bulk of serogroup C isolates. Whether this change in type of capsular polysaccharide expression in a different genotype affects transmission, carriage, virulence, or other aspects of meningococcal biology is unknown. The timing of the capsular switches that we identified is also unknown. In the case of the Hajj serogroup W-135 outbreak, the serogroup C capsular switch appears to have occurred long before the onset of the 2000 outbreak in Saudi Arabia but may have been selected for by serogroup A/C polysaccharide vaccine pressure in Hajj pilgrims [11] . In contrast, Vogel et al [12] demonstrated rapid capsular switching in the case of a teenage girl who died of ST-32 serogroup B meningococcal disease and her boyfriend, who had pharyngeal carriage with an otherwise indistinguishable serogroup C strain. Although it is generally assumed that the serogroup of the progenitor in a capsular switch is the one most commonly associated with the genetic lineage, in reality the direction of the switch is unknown.
For serogroups B and Y isolates, !2% demonstrated capsular switching. However, almost 13% of serogroup C isolates be- longed to genetic lineages associated with other serogroups, mostly serogroup B. This suggests that fewer barriers exist for the acquisition of the serogroup C capsular genes. A geneconversion event to change the specificity of the capsule polymerase from (a2r8)-linked polysialic acid (serogroup B) to (a2r9)-linked polysialic acid (serogroup C) may be facilitated by the close similarity of the DNA sequence of the gene between these serogroups. In addition, there is evidence for selection processes that favor or restrict transformation events, such as the differences in the restriction modification system noted between ST-11 and ST-32 isolates [47] . These hypotheses can be tested using in vitro experiments of horizontal gene transfer of meningococcal isolates of different serogroups and genetic lineages.
The Oregon serogroup B clone had previously been observed to have undergone capsular switching to serogroup C [9] . We identified 5 additional serogroup C isolates that were indistinguishable from the Oregon clone by MLST and OMP genotyping. We also identified a serogroup Y isolate in Colorado that belonged to the ST-32 complex (ST-6065) and had the same OMP genotype profile as the Oregon clone. We also observed the Oregon serogroup B clone causing disease in 7 of the 9 other ABCs sites. However, circulation of the Oregon clone has not resulted in hyperendemic serogroup B disease in these other sites, as it has in Oregon [39] . The reasons for this are not clear, but continued surveillance is required.
In summary, we have defined the population and antigenic structure of invasive meningococcal isolates at ABCs sites throughout the United States. Capsular switching was common, particularly among serogroup C isolates. Capsular switching from virulent serogroup C and Y lineages to serogroup B with clonal expansion is one mechanism by which replacement serogroup B disease could occur after the introduction of meningococcal conjugate vaccine. Although this has not occurred after the introduction of monovalent serogroup C conjugate vaccines in the United Kingdom [48] , the broader serogroup coverage of MCV4 could conceivably have a larger effect. Continuing to monitor for these events will be an important com-ponent of N. meningitidis surveillance in the setting of new meningococcal vaccines in the United States.
